MedTrace Logo

First Line Therapy for Patients With Metastatic Breast Cancer

NCT00456846 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2019-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m\^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes as part of their adjuvant therapy and patients who did not receive taxanes as part of their adjuvant therapy.

Conditions

Interventions

DRUG

ABI-007

100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Sasha Smiljanik, MD · Lions Gate Hospital

  • Kara Laing, MD · Dr. H. Bliss Murphy Cancer Center

  • Wendy Lam, MD · BC Cancer Agency-Burnaby

  • Maureen Trudeau, MD · Toronto Sunnybrook Cancer Centre

  • Vanessa Bernstein, MD · B.C.C.A. Vancouver Island Center

  • Jawaid Younus, MD · London Regional Cancer Centre

  • Lawrence Panasci, MD · McGill University

  • Guy Cantin, MD · CHA: Saint Sacrement Hospital

  • Nicolas Raymond, MD · Hospital de la Cite-de-la Sante-de-Laval

  • Robert El-Maraghi, MD · The Royal Victoria Hospital

  • Christine Brezden-Masley, MD · Unity Health Toronto

  • Andre Robidoux, MD · Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu

  • Martin Blackstein, MD · MOUNT SINAI HOSPITAL

  • Caroline Hamm, MD · Windsor Regional Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-01
Primary Completion
2012-12-11
Completion
2013-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456846 on ClinicalTrials.gov